Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
2.750
-0.190 (-6.46%)
At close: Jun 26, 2026, 4:00 PM EDT
2.500
-0.250 (-9.09%)
After-hours: Jun 26, 2026, 8:00 PM EDT
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$81,000
Profits / Employee
-$1,965,600
Market Cap
6.41M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| NextCure | 40 |
| Imunon | 20 |
| NuCana | 12 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 10 |
| Acurx Pharmaceuticals | 4 |
| Creative Medical Technology Holdings | 4 |
| Silo Pharma | 3 |
CANF News
- 1 day ago - Can-Fite BioPharma (CANF) Secures Key Patent for Fat Loss Treatment - GuruFocus
- 1 day ago - Can-Fite BioPharma secures Japanese patent for A3 adenosine receptor agonists - TheFly
- 1 day ago - Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology - GlobeNewsWire
- 5 days ago - Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson - GlobeNewsWire
- 10 days ago - Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026 - GlobeNewsWire
- 25 days ago - Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism - GlobeNewsWire
- 5 weeks ago - Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market - GlobeNewsWire
- 6 weeks ago - Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital - TheFly